vs
Side-by-side financial comparison of Climb Global Solutions, Inc. (CLMB) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Climb Global Solutions, Inc. is the larger business by last-quarter revenue ($182.4M vs $103.7M, roughly 1.8× Twist Bioscience Corp). Climb Global Solutions, Inc. runs the higher net margin — 1.8% vs -29.4%, a 31.2% gap on every dollar of revenue. On growth, Climb Global Solutions, Inc. posted the faster year-over-year revenue change (32.1% vs 16.9%).
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
CLMB vs TWST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $182.4M | $103.7M |
| Net Profit | $3.3M | $-30.5M |
| Gross Margin | 14.5% | 52.0% |
| Operating Margin | 2.1% | -31.7% |
| Net Margin | 1.8% | -29.4% |
| Revenue YoY | 32.1% | 16.9% |
| Net Profit YoY | -9.5% | 3.4% |
| EPS (diluted) | $0.18 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $103.7M | ||
| Q3 25 | $161.3M | — | ||
| Q2 25 | $159.3M | — | ||
| Q1 25 | $138.0M | — | ||
| Q4 24 | $161.8M | — | ||
| Q3 24 | $119.3M | — | ||
| Q2 24 | $92.1M | — |
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | $-30.5M | ||
| Q3 25 | $4.7M | — | ||
| Q2 25 | $6.0M | — | ||
| Q1 25 | $3.7M | — | ||
| Q4 24 | $7.0M | — | ||
| Q3 24 | $5.5M | — | ||
| Q2 24 | $3.4M | — |
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | 52.0% | ||
| Q3 25 | 15.9% | — | ||
| Q2 25 | 16.5% | — | ||
| Q1 25 | 16.9% | — | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 20.3% | — | ||
| Q2 24 | 20.2% | — |
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | -31.7% | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 5.0% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 7.2% | — | ||
| Q3 24 | 7.1% | — | ||
| Q2 24 | 4.6% | — |
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | -29.4% | ||
| Q3 25 | 2.9% | — | ||
| Q2 25 | 3.7% | — | ||
| Q1 25 | 2.7% | — | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 4.6% | — | ||
| Q2 24 | 3.7% | — |
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $-0.50 | ||
| Q3 25 | $1.02 | — | ||
| Q2 25 | $1.30 | — | ||
| Q1 25 | $0.81 | — | ||
| Q4 24 | $1.52 | — | ||
| Q3 24 | $1.19 | — | ||
| Q2 24 | $0.75 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.8M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $118.4M | $456.1M |
| Total Assets | $458.8M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $197.9M | ||
| Q3 25 | $49.8M | — | ||
| Q2 25 | $28.6M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $22.1M | — | ||
| Q2 24 | $48.4M | — |
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $456.1M | ||
| Q3 25 | $109.3M | — | ||
| Q2 25 | $105.2M | — | ||
| Q1 25 | $95.6M | — | ||
| Q4 24 | $90.6M | — | ||
| Q3 24 | $87.7M | — | ||
| Q2 24 | $79.8M | — |
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $638.1M | ||
| Q3 25 | $376.1M | — | ||
| Q2 25 | $420.7M | — | ||
| Q1 25 | $370.1M | — | ||
| Q4 24 | $469.2M | — | ||
| Q3 24 | $371.9M | — | ||
| Q2 24 | $302.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-11.9M | $-24.8M | ||
| Q3 25 | $22.2M | — | ||
| Q2 25 | $-2.2M | — | ||
| Q1 25 | $8.5M | — | ||
| Q4 24 | $16.0M | — | ||
| Q3 24 | $-3.6M | — | ||
| Q2 24 | $7.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -1.70× | — | ||
| Q3 25 | 4.73× | — | ||
| Q2 25 | -0.37× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | -0.66× | — | ||
| Q2 24 | 2.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLMB
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
